The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer by F. Zugni et al.
RESEARCH ARTICLE
The added value of whole-body magnetic
resonance imaging in the management of
patients with advanced breast cancer
Fabio ZugniID1*, Francesca Ruju2, Paola Pricolo2, Sarah Alessi2, Monica Iorfida3, Marco
Angelo Colleoni3, Massimo Bellomi2,3,4, Giuseppe Petralia2,3,4
1 Post-graduation school in Radiodiagnostics, University of Milan, Milan, Italy, 2 Department of Radiological
Science and Radiation Therapy, European Institute of Oncology (IEO), Milan, Italy, 3 Division of Medical
Senology, European Institute of Oncology (IEO), Milan, Italy, 4 Department of Oncology, University of Milan,
Milan, Italy
* fabio.zugni@unimi.it
Abstract
This study investigates the impact of whole-body MRI (WB-MRI) in addition to CT of chest-
abdomen-pelvis (CT-CAP) and 18F-FDG PET/CT (PET/CT) on systemic treatment deci-
sions in standard clinical practice for patients with advanced breast cancer (ABC). WB-MRI
examinations in ABC patients were extracted from our WB-MRI registry (2009–2017).
Patients under systemic treatment who underwent WB-MRI and a control examination (CT-
CAP or PET/CT) were included. Data regarding progressive disease (PD) reported either
on WB-MRI or on the control examinations were collected. Data regarding eventual change
in treatment after the imaging evaluation were collected. It was finally evaluated whether the
detection of PD by any of the two modalities had induced a change in treatment. Among 910
WB-MRI examinations in ABC patients, 58 had a paired control examination (16 CT-CAP
and 42 PET/CT) and were analysed. In 23/58 paired examinations, additional sites of dis-
ease were reported only on WB-MRI and not on the control examination. In 17/28 paired
examinations, PD was reported only on WB-MRI and not on the control examination. In 14
out of the 28 pairs of examinations that were followed by a change in treatment, PD had
been reported only on WBMRI (14/28; 50%), while stable disease had been reported on the
control examination.
In conclusion, WB-MRI disclosed PD earlier than the control examination (CT-CAP or
PET/CT), and it was responsible alone for 50% of all changes in treatment.
Introduction
Advanced breast cancer (ABC) encompasses metastatic (MBC) and locally advanced breast
cancer (LABC). MBC is still an incurable disease with a 5-year survival rate between 15% and
27% [1,2], and progression to MBC occurs in about 20–30% of non-metastatic patients [3].
LABC is diagnosed at presentation in 8.5% of American and 4% of European patients with
breast cancer, and despite aggressive treatment, many of these patients eventually progress to
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MBC, with a 5-years survival rate between 15% and 50% [1]. Once the diagnosis if ABC is
made, a systemic antineoplastic treatment is offered, including endocrine therapy, chemother-
apy or targeted therapy. The most common site of metastases is bone, with more than 70% of
those who die from breast cancer having evidence of bone metastases [4], followed by liver,
pleura, peritoneum, lung, distant lymph nodes and central nervous system [5].
In addition, a recent meta-analysis including 127,324 patients demonstrated that during a
5-years follow-up a median of 12.2% of non-metastatic breast cancer patients (stages I-III) will
develop bone metastases [6]. Bone disease can impact on quality of life, causing skeletal related
events (SREs): with significant health economic implications [7].
Recognizing metastatic disease progression promptly and confidently is crucial for ABC
management, since it allows for a timely initiation of a new line of therapy. Evaluation of
response to treatment in ABC patients can be performed using several imaging modalities [8].
The most widely available is computerised tomography (CT) which provides a good compro-
mise between quickness, feasibility, cost-effectiveness and reproducibility of the examination.
Evaluation of disease response or progression on CT relies mainly on morphologic modifica-
tions; the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 are the most
widely accepted for this purpose [9]. However, CT shows limitations in the evaluation of
patients with bone-predominant MBC. In fact, RECIST consider bone metastases to be non-
measurable [9]. The MD Anderson Cancer Centre criteria [10] have provided other CT fea-
tures for defining sclerotic response to treatment and progression. Unfortunately, in patients
that show heterogeneous response to treatment and in those who have bone only disease, these
criteria cannot be applied. Moreover, these criteria are not valid in patients who receive anti-
osteoclastic therapy (bisphosphonates). 18F-Fluorodeoxyglucose positron emission tomogra-
phy (PET/CT) is a functional imaging modality that depicts the intensity of glucose metabo-
lism across different body regions. This feature allows PET/CT to assess disease response or
progression by revealing changes in metabolic activity within neoplastic tissue even without
the evidence of morphological changes. Despite the overall better diagnostic performance of
PET/CT compared to CT and bone scintigraphy, these two remain the most widely recom-
mended in the follow-up of ABC patients [11]. This is also due to differences in availability
but, more importantly, to the absence at present of a clear advantage in terms of cost-benefit
ratio. The European School of Oncology–Metastatic Breast Cancer (ESO-MBC) Task Force
guidelines state that PET/CT is not recommended for routine restaging of MBC patients.
“Alternative” radiotracers might play a role in the future for the follow-up and response-evalu-
ation of MBC patients in specific settings, as in the case of tumour heterogeneity. 89Zr-trastu-
zumab has been used for the detection of human epidermal growth factor 2 (HER2)-positive
metastases developed in patients with HER2-negative tumours [12]; 18F-Fluciclovine uptake
has shown good correlation with treatment response to neoadjuvant systemic treatments [13],
as well as a higher sensitivity for infiltrating lobular carcinoma (ILC) [14]. Whole-body PET/
MRI is a hybrid imaging modality that merges the advantages of both techniques. Although
ideally suitable for the long term surveillance of cancer survivors due to the reduced radiation
dose compared to PET/CT [15], current studies are mainly focusing on its use for disease stag-
ing [16] and response evaluation after neoadjuvant treatments [17]. At present, the true added
value of simultaneous PET/MRI, as compared to PET/CT and MRI, remains to be determined
[15].
Whole-body magnetic resonance imaging (WB-MRI) is emerging as a promising bone
marrow assessment tool for detection and therapy monitoring of bone metastases in different
tumour types [18–20].WB-MRI features T1 and T2 sequences for morphologic evaluation, as
well as diffusion-weighted imaging (DWI) which highlights areas of reduced water diffusivity
within tissues. Previous publications have provided criteria for the use of WB-MRI for therapy
WB-MRI in the management of advanced breast cancer
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monitoring of MBC patients [20,21], which rely on DWI as indirect but solid biomarker of tis-
sue cellularity [22]. DWI enables the radiologist to rapidly recognize the presence and evolu-
tion of metastatic disease, providing early signs of disease response or progression [21].
Apparent Diffusion Coefficient (ADC) maps derive from a quantitative analysis of diffusion-
weighted images; ADC values show an inverse correlation with cellularity in many tumour his-
totypes, including breast cancer [23]. Evaluating the findings highlighted by DWI according to
their corresponding ADC values helps differentiating benign from malignant lesions [24].
Notably, DWI alone is not always accurate this task [25], therefore correlation with morpho-
logic T1 and T2 images is mandatory for avoiding false-positive and false-negative results [26].
One of the strengths of WB-MRI is that it can be performed in clinically acceptable examina-
tion times (30–40 min). Two other great advantages include the lack of contrast injection and
ionising radiation. Due to the superior sensitivity for initial bone infiltration, WB-MRI has
become the gold standard in the diagnosis and assessment of multiple myeloma [27,28].
Guidelines for acquisition, interpretation and reporting of WB-MRI in advanced prostate can-
cer [29] have recently been published, as a support for the increasing use of WB-MRI in meta-
static and high-risk prostate cancer. Due to high performance in bone-metastatic tumours,
WB-MRI has been naturally suggested for the evaluation of MBC. At our centre, an increasing
number of patients with bone-predominant or bone-only MBC is being evaluated using
WB-MRI, alongside other whole-body imaging modalities such as CT-CAP and PET/CT. Two
imaging modalities may occasionally be performed at the same time point for the characteriza-
tion of complex metastatic patterns, unclear tumour behaviour, or when the hypothesis of dis-
ease progression is affected by discordant data.
This retrospective study of our practice in the evaluation of ABC patients under systemic
treatment investigates whether the use of WB-MRI in addition to chest-abdomen-pelvis CT
(CT-CAP) or PET/CT brings an additional benefit in patient management, allowing for earlier
changes of ineffective treatments.
Methods and materials
Population
We interrogated an ongoing registry including all WB-MRI performed in our institute from
February 1st 2009 to April 31st 2017 (2444 examinations). We included in the study all
WB-MRI performed on ABC patients undergoing systemic treatment; all examinations per-
formed for baseline disease staging were excluded. All WB-MRI performed within 8 weeks
from a CT-CAP or an 18F-FDG PET/CT were included in the study. Each WB-MRI included
in the study was therefore paired to a CT-CAP or a PET/CT (defined as “control examina-
tions”) performed under the same systemic treatment. Patient’s medical records were made
available for all included examinations; more specifically, we collected the medical records
compiled at the start of the ongoing treatments, and those compiled immediately after each
pair of examinations (within one month). The ethics committee of our institution (European
Institute of Oncology, Milan) approved this study. The ethics committee waived the require-
ment for informed consent, as this retrospective study did not alter or influence the diagnostic
and therapeutic paths of the patients, involving summary data from imaging reports and medi-
cal records.
Imaging technique
Our WB-MRI protocol Table 1, consisting of sagittal T1-weighted and T2-weighted sequences
on the whole spine, axial T1 weighted, T2-weighted and DWI from head to mid-thigh, was
performed on a 1.5 T scanner (Magnetom Avanto, Siemens Healthcare Sector, Erlangen,
WB-MRI in the management of advanced breast cancer
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Germany). Anatomy-specific phased-array surface coils were used for all body regions. The typical
cumulative WB-MRI data acquisition time was 40 minutes. Post-processing included in-line
(Water e Fat images, ADC maps) and off-line reconstruction (Radial maximum intensity projec-
tions of high b-value images, multi-plane reconstructions and relative fat-fraction maps). CT-CAP
and 18FDG PET-CT were performed using each imaging department’s standard imaging protocols.
CT-CAP always included intravenous contrast administration. All the original WB-MRI scans
were reported by a pool of three radiologists (one senior radiologist and two junior radiologists
who were supervised by the senior one, with an experience of 8, 5 and 4 years respectively in onco-
logical WB-MRI). As to the occurrence of stable or progressive disease, particularly in the skeleton,
images were interpreted according to the criteria proposed by Padhani et al. [21].
Data collection
Two residents in radiology with 3 and 1 years’ experience in WB-MRI reporting independently
extracted the relevant data from the original reports of WB-MRI and the control examinations.
Firstly, data regarding the reported extent of disease were collected, annotating the presence or
absence of metastases categorized by 7 sites: bone, primary site, lymph nodes (including
regional and distant), liver, lung/pleura, peritoneum/retroperitoneum (including stomach,
bowel, intra and retro-peritoneal fat), other.
Sites of metastatic disease reported by only one of the two modalities (either WB-MRI or
the control examination) were annotated and termed additional sites (AS). Discordance on
the assessment of disease extent was defined as the presence of one or more AS reported by
one of the two modalities.
Secondly, reports were reviewed to determine whether WB-MRI and/or the control exami-
nation had described progression of disease (PD), defined as the increased extent of the disease
compared to the patient’s known baseline at the start of the ongoing treatment. Discordance
on reported PD was defined as occurring when WB-MRI and the control examination reports
concluded with different assessments (i.e. PD opposed to stable disease). When only one
modality described PD, the sites of disease in which PD was reported were annotated.
Table 1. Scanning parameters for WB-MRI.
Scanning parameters (1,5T) Chest—Abdomen—Pelvis Spine DWI
Image Contrast T1 T2 T1 T2 DWI
In/Out-Phase
Imaging Sequence DIXON HASTE TSE TSE SSH SE EPIa
Orientation Axial Axial Sagittal Sagittal axial
Echo / Repetition Time (ms) 2.39–4.77 / 6.65 74 / 800 9.3 / 350 60 / 2560 62 / 6550
Field of view (mm) 430 430 400 400 430
Matrix 352 x 209 320 x 175 448 x 224 320 x 160 132 x 120
Slices per Station / Stations 72 / 4 176 / 1 16 / 2 16 / 2 50 / 4
Flip angle (degrees) 20.5 149 150 150 -
Slice Thickness / Gap (mm) 3.5 / 0.7 5 /1 4 / 0.4 4 / 0.4 5 / 0
Fat Suppression . . . . . . . . . STIR STIR
Respiratory Control Breath-Hold Breath-Hold . . . . . . Free-breathing
Diffusion Encoding:
b-values (s/mm2)
. . . . . . . . . . . . 50, 900
Acquisition Time (min:sec) 1:04 2:30 3:32 3:10 15:02
a Single-Shot Spin Echo Planar Imaging
https://doi.org/10.1371/journal.pone.0205251.t001
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Thirdly, data were collected regarding all cases in which the ongoing treatment was
changed as result of the imaging response. In all cases of discordance between the two modali-
ties, data were collected as to whether the PD reported by one of the two examinations had
motivated a change in treatment, as stated in each patient’s medical record.
Results
A total of 910 WB-MRI examinations were performed on ABC patients in the selected period.
Fifty-eight WB-MRI were paired to a control examination: 16 (28%) to CT-CAP and 42 (72%)
to PET/CT. The median age of the included patients was 56 years (range, 36–80 years). Infor-
mation on the characteristics of the breast cancers in these patients is summarized in Table 2.
The median time distance between WB-MRI and the control examination was 27 days (range,
1–54 days). In 40 pairs of examinations (69%) the status of the patient at the time of the evalua-
tion was M1, while in 18 pairs (31%) it was M0 (no prior history of metastases).
Extent of disease
Out of the 58 paired examinations, metastases were reported in 49 WB-MRI and in 39 control
examinations. Bone metastases were the most frequent, reported by 37 WB-MRI and by 30
control examinations. The second most frequent site of metastases was lymph nodes, reported
in 15 WB-MRI and in 18 control examinations. Discordant assessments on disease extent were
Table 2. Breast cancer characteristics in our study population.
N %
Histology
IDC 37 64%
ILC 19 32%
Other 1 2%
Unknown 1 2%
Grade
1 2 3%
2 23 40%
3 18 31%
Unknown 15 26%
ER
Positive 54 93%
Negative 4 7%
PgR
Positive 53 91%
Negative 5 9%
HER2
Positive 31 53%
Negative 24 41%
Unknown 3 5%
M
Positive 40 69%
Negative 18 31%
Abbreviations: IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; ER = oestrogen receptor;
HER2 = human epidermal growth factor 2; M = metastatic status.
https://doi.org/10.1371/journal.pone.0205251.t002
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observed in 28 paired examinations. AS were reported in 23 WB-MRI and in five control
examinations, all of which were PET/CT. The distribution of the AS is summarized in Table 3.
Assessment of progressive disease
Of the 58 pairs of examinations, SD was reported in 18 pairs and PD in a total of 40 pairs. PD
was reported by both examinations in 23 out of 40 pairs, while in the other 17 it was only
reported by WB-MRI, with the control examination reporting SD. Table 4 summarizes the
anatomical distribution of the sites of PD detected only by WB-MRI and of those detected by
both examinations. Twelve out of 18 non-metastatic (M0) patients were up-staged to M1, in
seven of these, PD was reported only on WB/MRI.
Change in treatment
A change in treatment was made in 28 out of 40 pairs as a result of PD; in 12 pairs therapy was
continued despite evidence of PD. Overall, treatment was changed because of PD in 28 epi-
sodes, of which 14 (50%) were due to PD reported only by WB-MRI Fig 1. Separate analyses
for the paired evaluations in which WB-MRI was compared to CT-CAP and to PET/CT are
graphically described in Fig 1. Inside the subgroup of 19 paired examinations in patients with
Table 3. Distribution of the additional sites of disease (AS) reported by WB-MRI and by the control examination respectively.
AS in WB-MRI AS in the control examination (PET/CT)
8 bone only 0 bone only
5 bone + visceral/soft tissues 1 Liver 1 bone + visceral/soft tissues 1 lung/pleura
1 Liver + lymph nodes
2 Lymph nodes
1 Peritoneum/retroperitoneum
10 Visceral/soft tissues 5 Peritoneum/retroperitoneum 4 Visceral/soft tissues 3 Lymph nodes
2 Lung/pleura
1 Liver
1 Local 1 Peritoneum/retroperitoneum
1 Other
23 Total 5 Total
https://doi.org/10.1371/journal.pone.0205251.t003
Table 4. Distribution of the sites of progressive disease (PD) reported only at WB-MRI and of those reported at both examinations.
PD reported by both examinations in 23 pairs PD reported only by WB-MRI in 17 pairs PD reported only by the
control examination in 0
pairs
9 Bone 8 Bone 0 Bone
12 Bone + visceral/soft tissues 3 Lymph nodes 4 Bone + visceral/soft tissues 2 Lymph nodes 0 Bone + visceral/soft tissues
2 Lymph nodes + liver
1 Lymph nodes + lung/pleura 1 Limph nodes + liver
1 Lymph nodes + other
2 Lung/pleura
2 Peritoneum/retroperitoneum 1 Peritoneum/retroperitoneum
1 Liver
2 Visceral/soft tissues 1 Lymph nodes 5 Visceral/soft tissues 3 Peritoneum/retroperitoneum 0 Visceral/soft tissues
1 Lung/pleura
1 Lymph nodes + lung/pleura 1 Local
https://doi.org/10.1371/journal.pone.0205251.t004
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Fig 1. Impact on treatment: Overall and subgroup analyses. The flowcharts in this picture illustrate how often the
imaging outcomes motivated changes of treatment in our cohort, with a distinction between the cases of PD reported
only on WB-MRI and those in which PD was reported on both examinations (WB-MRI and the control examination).
The first flowchart includes all 58 paired examinations (overall analysis). Separate analyses are shown for specific
subgroups in the following flowcharts, including analyses of all 16 paired examinations in which WB-MRI was paired
WB-MRI in the management of advanced breast cancer
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ILC, therapy was changed because of PD in 10; PD was reported only on WB-MRI in seven of
these (7/10; 70%) Fig 1. The most frequent AS in this subgroup was bone, being reported in
seven WB-MRI, while the second was peritoneum/retroperitoneum, reported in four. Inside
the subgroup of 18 paired examinations in M0 patients, therapy was changed because of PD in
eight; PD was reported only on WB-MRI in six of these (6/8; 75%). Supporting information
to CT-CAP, all 42 paired examinations in which WB-MRI was paired to PET/CT and all 19 paired examinations
performed in ILC patients. Abbreviations: PD = progressive disease; SD = stable disease.
https://doi.org/10.1371/journal.pone.0205251.g001
Fig 2. Nodal recurrence or progression to metastatic disease? 36 years old woman with locally advanced ductal breast cancer, after surgery (pT1 N1a M0), local
radiation therapy and adjuvant chemotherapy. While under endocrine treatment, an axillary nodal recurrence is diagnosed (histologically proven). In the suspicion of
distant metastases, the patient underwent FDG-PET/C. Coronal FDG-PET MIP (a) showed uptake in left axillary lymph nodes (white arrowhead), with no other
finding suspicious for metastases. WB-MRI was performed 15 days later: DWI b-900 MIP (b) confirmed the left axillary lymph node metastases (white arrowhead),
and detected metastases in bone (left iliac bone, right sacral wing; black arrows), in liver (II and VI segments; white arrows), in lymph nodes (right parasternal, left
internal mammary, hepatic hilar, para-aortic and lumbar; red arrows) and in subcutaneous parasternal tissues (black arrowhead). Normal areas of high signal can be
seen in cervical and pelvic lymph nodes, brain, spinal cord, spleen, kidneys and in bilateral ovarian cysts. The PD reported at WB-MRI determined a change in
treatment from Letrozole to capecitabine, vinorelbine and cyclophosphamide, with additional radiation therapy on bone lesions.
https://doi.org/10.1371/journal.pone.0205251.g002
WB-MRI in the management of advanced breast cancer
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for this paper include detailed information on the extent of disease, sites of PD and impact on
systemic treatment for all pairs of examinations, S1 Table.
Discussion
Extent of disease
As expected, in our study the most frequent site of metastatic findings in all modalities was
bone, being bone the most common site of metastases in breast cancer [30]. The second and
third most common sites of metastases in both modalities were lymph nodes and lung/pleura,
as well mirroring the common metastatic pattern reported in literature. Bone was also the
most frequent additional site (AS) of disease reported by WB-MRI and not by the control
examination (Figs 2–4). A meta-analysis on the detection of bone metastases [31] has indeed
reported sensitivity/specificity on a per-patient basis for MRI of 90.6% and 95.4%, proving it to
be superior to CT with sensitivity/specificity of 72.9% and 94.8, and comparable to PET, with
sensitivity/specificity of 89.7% (95% CI: 87.4–91.6%) and 96.8% (95% CI: 96.2–97.3%).
The second most frequent AS on WB-MRI was peritoneum/retroperitoneum (Figs 5 and
6). MRI could be able to reveal peritoneal or retroperitoneal disease more confidently by
means DWI, which can highlight small metastatic foci within normal tissues. In a study
including 32 patients from Michielsen et al. WB-MRI (with DWI), PET/CT and CT were com-
pared in the detection of peritoneal and retroperitoneal metastases of ovarian primary, with
surgery as standard of reference. In this study WB-MRI was excellent in the detection of intra-
peritoneal disease, with sensitivity/specificity of 91% and 91%, compared to 65% and 82% for
CT, and 52% and 85% for PET/CT, and was equivalent in the detection of retroperitoneal dis-
ease compared to PET/CT [32]. In another study including 26 patients from Fujii et al., the
sensitivity and specificity of DWI for peritoneal carcinosis were 90% and 95.5%, respectively
[33]. In our study, in 4 out of 6 WB-MRI with AS in peritoneum/retroperitoneum, the
Fig 3. In the same pair of examinations of Fig 2, axial fused FDG-PET/CT showed non-specific FDG uptake in the
pelvic bones (a). T1 weighted axial image from WB-MRI showed a suspicious bone lesion in the left iliac bone (arrow
in b), which was hyperintense on b-900 DWI images (arrow in c) with low ADC values (d).
https://doi.org/10.1371/journal.pone.0205251.g003
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histology of the primary was ILC. This observation suggests that WB-MRI might be particu-
larly suited for the assessment of ILC patients compared to CT and PET/CT. In ILC, metastatic
spread to the gastrointestinal tract and to peritoneum/retroperitoneum is particularly frequent
[34], and CT might be sometimes unable to detect these localizations, also because of its
reduced sensitivity for small nodules (below 10 mm size) in the abdominal cavity [35] and in
the retroperitoneum [36]. ILC, due to characteristic loss of E-cadherin adhesion protein [37],
presents an un-aggregated growth [38], making metastases less measurable. PET/CT as well
has a pitfall for small metastatic lesions below its spatial resolution, especially in the colon or in
the small bowel where non-specific FDG uptake is often reported [39,40]. Moreover, the low
FDG avidity of ILC [41] reduces the value of PET/CT for the detection of bone metastases in
ILC [42].
Most of the AS reported by the control examination were in lymph nodes, being found in 3
PET/CT (sub-clavicular, hilar or mediastinal lymph nodes). This result might be related to the
superior sensitivity and specificity of PET/CT (SE 98%,SP 83%) for lymph nodes compared to
MRI in mediastinum (SE 80%, SP 75%) [43,44].
Assessment of progressive disease and change in treatment
There were 17 episodes of PD reported only on WB-MRI and not reported on the control
examination, accounting for 43% (17/40) of all cases of PD. Among these, 14 determined a
change in treatment, accounting for 50% (14/28) of all changes after imaging evaluation. Eval-
uating these patients by means of WB-MRI resulted in a detection of PD that would have oth-
erwise been recognized weeks or months later. This allowed the oncologists to interrupt
Fig 4. In this picture, taken from the same examination of Figs 2 and 3, two different examples of high signal intensity findings in DWI b-900 MIP (a) are
illustrated. (b) B-900 DWI images reveal two new hyper intense lesions in the left liver lobe (arrows). (c) In the correspondent ADC map, the lesions (arrows)
show low values, which suggest high cellularity, making them suspicious for metastases. (d) B-900 DWI images show bilateral pelvic masses with high signal
intensity (arrowheads). (e) The correspondent ADC maps shows the absence of impeded diffusion within the masses, that represent follicular ovarian cysts.
https://doi.org/10.1371/journal.pone.0205251.g004
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ineffective treatments earlier, before the potential onset of acute complications of PD, such as
SREs. The scope and methodology of our work are in line with a previously published work by
Kosmin et.al.[45] that evaluates the impact of WB-MRI alongside CT-CAP on the manage-
ment of MBC patients under systemic treatment. The study by Kosmin et.al. [45] showed that
WB-MRI had an impact on treatment management in nearly 35% of all cases (where 16/46 of
all changes in treatment were due to PD reported only on WB-MRI and not on CT-CAP). In
the subgroup of WB-MRI paired to CT-CAP within our study, the impact of WB-MRI on
treatment management was 70%. The greater impact of WB-MRI observed in our study could
be due to different factors. In the study by Kosmin the time between WB-MRI and the control
examination was below two weeks, therefore the greater interval between the examinations in
our study could have allowed variations of the actual disease extent. A second reason for the
different result could be the difference in population: 33% (19/58) of our examinations were
performed on ILC patients while these formed only 12% of the population studied by Kosmin.
We believe that the higher frequency of ILC patients in our study compared to the normal rate
in breast cancer population (approximately 15%) [46] might have amplified the impact of
WB-MRI on the detection of metastases. Thirdly, the presence of M0 patients in our cohort
might have amplified the impact of WB-MRI on patient management, since the detection of
metastases in these patients has a greater chance of leading to a change in treatment. Interest-
ingly, there were no cases of PD reported only on the control examination, since all the AS
reported on PET/CT occurred in episodes of PD involving also other anatomical sites, which
were reported on both modalities.
Fig 5. Peritoneal carcinosis undetected at PET/CT. Patient with locally advanced ductal breast carcinoma (pT2, N2a,
M0) after surgery and 4 cycles of chemotherapy, under endocrine therapy. After suspicious rise in CA15-3 the patient
underwent FDG-PET/CT, which showed no suspicious uptake and was reported as negative for distant metastases.
Sagittal MIP (a) showed non-specific FDG uptake in the ascending colon and tracer excretion in the urinary tract.
Pelvic axial cross-section of the FDG-PET/CT (b) and the co-registered CT image (c) did not show any suspicious
uptake or measurable lesion.
https://doi.org/10.1371/journal.pone.0205251.g005
WB-MRI in the management of advanced breast cancer
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There are some limitations to this study. Firstly, it was performed retrospectively without a
new image analysis. This implies a certain degree of inhomogeneity between the original
reports in terms of communication structure and level of detail, especially among the control
examinations.We believe however that this kind of analysis is more relatable to true clinical
practice. Secondly, the distance (median 27 days) between WB-MRI and the control examina-
tions is quite high. It is important to note, however, that ours is not a perspective study, in
which the schedule of imaging controls is fixed in the most convenient way. When oncologists
in our institute program WB-MRI for an ABC patient, other imaging modalities such as CT or
PET/CT are dismissed or sometimes interleaved at 3–6 months. This implies a subjective
choice by the oncologist: indeed ESMO guidelines for ABC do not recommend a specific
modality for follow-up [8]. These factors, combined with the waiting list for WB-MRI slots,
motivated the quite high distance between WB-MRI and control examinations. Based on the
findings of this study, we are currently planning a perspective study with a distance between
WB-MRI and the control examination within seven days. Thirdly, our study does not address
an eventual impact of WB-MRI on patient survival. This limitation is common to other imag-
ing studies. Nevertheless, the earlier detection of PD and the subsequent changes in treatment
might help delaying the onset of SREs and of other acute complications in metastatic patients,
with a potential impact on quality of life and disability.
In conclusion, WB-MRI disclosed PD earlier than the control examination (CT-CAP or
PET/CT) and it was responsible alone for 50% of all changes in treatment in our cohort. Larger
and prospective studies are therefore encouraged to validate our observations in ABC patients.
Supporting information
S1 Table. Detailed results for all paired evaluations. Abbreviations: G = grade;
ER = oestrogen receptor status; PG = progesterone receptor status; HER2 = expression of
Fig 6. In the same patient of Fig 5, the paired WB-MRI showed thickening of the peritoneum in the right pelvis, which
was hyper-intense in DWI b-900 sagittal MIP (a) and DWI axial b-900 images (arrow in b), with corresponding
reduced ADC values (c). Axial T1 and T2 images confirmed the presence of a suspicious thickening of the right pelvic
peritoneum and mesorectal fascia (arrows in d and e). No significant fluid collection can be seen. Other benign high
signal intensity areas in the MIP image (a) include salivary glands, spinal cord, silicon breast implant, spleen, kidneys,
small bowel and a bartholin’s gland cyst. The PD reported at WB-MRI determined a change in treatment from
Letrozole to Fulvestrant.
https://doi.org/10.1371/journal.pone.0205251.g006
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human epidermal growth factor receptor 2; M+ = metastatic status (TNM); S = site of disease;
AS = additional site of disease; AS (PD) = additional site of disease that determined the out-
come of PD; SD = stable disease; PD = progressive disease; PD (MRI only) = PD reported only
on WB-MRI.
(XLSX)
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